Addition of elotuzumab ups PFS in refractory multiple myeloma
(HealthDay)—For patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor has failed, progression-free survival (PFS) is longer in those receiving the immunostimulatory monoclonal antibody ...
Nov 8, 2018
0
0